OTA for prototype, ebola virus
Active Other Transaction Agreement Awarded Last action
- Contract number
- W911QY1690001
- Awardee
-
Gilead Sciences Inc. UEI FPJMGUK1BYH8
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $49,886,012
Award facts
- Contract value 83% obligated
-
- $57,853,080.86 Current, with exercised options
- $60,427,361.98 Potential, with all options
- Completion date 96% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- Foster City, CA 94404, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$5,488,170 | |
| Funding Only Action | -$222,361 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$152,833 | |
| Funding Only Action | -$2,095,258 | |
| Supplemental Agreement for work within scope | $426,360 | |
| Funding Only Action | $5,266,278 | |
| Supplemental Agreement for work within scope | $11,337,575 | |
| Funding Only Action | $472,342 | |
| Funding Only Action | -$1,475,793 | |
| Funding Only Action | $8,000,000 | |
| Funding Only Action | -$3,000,641 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $4,429,147 | |
| Funding Only Action | -$864,052 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $933,000 | |
| Funding Only Action | $2,739,981 | |
| Funding Only Action | $3,857,127 | |
| Funding Only Action | $4,000,000 | |
| Funding Only Action | $6,500,000 | |
| Funding Only Action | $1,107,921 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $4,437,462 | |
| Funding Only Action | $4,377,000 | |
| Modification | $7,172,869 | |
| Funding Only Action | $2,891,709 | |
| Funding Only Action | -$5,213,648 | |
| Funding Only Action | $450,000 |
Show all 33
About this award
The Department of Defense's Joint Program Executive Office for Chemical and Biological Defense awarded an Other Transaction Agreement to Gilead Sciences Inc. on August 17, 2016, with a ceiling value of $60,427,361.98 to develop broad-spectrum Ebola medical countermeasures under a prototype authority that sits outside the FAR. Work is performed in Foster City, California, with an ultimate completion date of March 30, 2027. The OTA authorizes prototype development for advanced antiviral medical countermeasures targeting multiple Ebola virus strains, leveraging Gilead's existing capabilities in antiviral pharmaceutical development and manufacturing.
Quick answers
Who was awarded contract W911QY1690001?
W911QY1690001 was awarded to Gilead Sciences Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on August 17, 2016.
How much is contract W911QY1690001 worth?
The government has obligated $49,886,012 on W911QY1690001. Its current value, with exercised options, is $57,853,081. Its potential value, with all options, is $60,427,362.
Which agency awarded contract W911QY1690001?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY1690001, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY1690001 competed?
The extent of competition for W911QY1690001 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award